Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study
In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant
tissue, but also in BAL fluid from patients with benign lung disease. This suggests that
DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this
hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with
lung cancer to controls who are current or former smokers with benign lung disease.
Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking
individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1
expression, the investigators will obtain serum samples from 20 control patients with lung
disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will
be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Tumor Markers in Lung Cancer:
DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.
Kellie Jones, MD
University of Oklahoma
United States: Institutional Review Board
|VAMC-OKC||Oklahoma City, Oklahoma 73104|